Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morning vs Evening Administration of Empagliflozin
NCT03895229Phase 1Completed
- Sponsor
- Ain Shams University
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Ain Shams University. Primary endpoints: Maximum drug concentration in plasma, Area under the plasma concentration-time curve from time 0 to 48 hours and 1 more. Started Oct 2018; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03895229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895229.